Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide

被引：0
作者：
J Bray
J Sludden
M J Griffin
M Cole
M Verrill
D Jamieson
A V Boddy
机构：
[1] Northern Institute for Cancer Research,
[2] Paul O'Gorman Building,undefined
[3] Medical School,undefined
[4] Newcastle University,undefined
[5] Northern Centre for Cancer Care,undefined
[6] Newcastle Freeman Hospital,undefined
来源：
British Journal of Cancer | 2010年 / 102卷
关键词：
breast cancer; doxorubicin; cyclophosphamide; pharmacogenetics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1003 / 1009
页数：6
相关论文
共 50 条
  • [1] Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide
    Bray, J.
    Sludden, J.
    Griffin, M. J.
    Cole, M.
    Verrill, M.
    Jamieson, D.
    Boddy, A. V.
    BRITISH JOURNAL OF CANCER, 2010, 102 (06) : 1003 - 1009
  • [2] Effects of pharmacogenetics on pharmacokinetics and toxicity of doxorubicin in Egyptian breast cancer patients
    Ebaid, N. F.
    Abdelkawy, K. S.
    Shehata, M. A.
    Salem, H. F.
    Magdy, G.
    Hussein, R. R. S.
    Elbarbry, F.
    XENOBIOTICA, 2024, 54 (03) : 160 - 170
  • [3] Cyclophosphamide bioactivation pharmacogenetics in breast cancer patients
    Nuala Helsby
    Minghan Yong
    Kathryn Burns
    Michael Findlay
    David Porter
    Cancer Chemotherapy and Pharmacology, 2021, 88 : 533 - 542
  • [4] Cyclophosphamide bioactivation pharmacogenetics in breast cancer patients
    Helsby, Nuala
    Yong, Minghan
    Burns, Kathryn
    Findlay, Michael
    Porter, David
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 88 (03) : 533 - 542
  • [5] Verbal memory in breast cancer patients treated with chemotherapy with doxorubicin and cyclophosphamide
    Andryszak, P.
    Wilkosc, M.
    Zurawski, B.
    Izdebski, P.
    EUROPEAN JOURNAL OF CANCER CARE, 2018, 27 (01)
  • [6] Low-dose filgrastim in patients with breast cancer treated with docetaxel, doxorubicin, and cyclophosphamide
    Ip, Eric J.
    Lee-Ma, Annette
    Troxell, Lawrence S.
    Chan, James
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2008, 65 (16) : 1552 - 1555
  • [7] Acute toxicity of adjuvant doxorubicin and cyclophosphamide for early breast cancer - a retrospective review with an historic of Chinese patients and comparison Western series
    Ma, B
    Yeo, W
    Hui, P
    Ho, WM
    Johnson, PJ
    RADIOTHERAPY AND ONCOLOGY, 2002, 62 (02) : 185 - 189
  • [8] Relationship between ABCB1 gene polymorphisms and severe neutropenia in patients with breast cancer treated with doxorubicin/cyclophosphamide chemotherapy
    Ikeda, Midori
    Tsuji, Daiki
    Yamamoto, Keisuke
    Kim, Yong-Il
    Daimon, Takashi
    Iwabe, Yutaro
    Hatori, Masahiro
    Makuta, Ryo
    Hayashi, Hideki
    Inoue, Kazuyuki
    Nakamichi, Hidenori
    Shiokawa, Mitsuru
    Itoh, Kunihiko
    DRUG METABOLISM AND PHARMACOKINETICS, 2015, 30 (02) : 149 - 153
  • [9] Doxorubicin/cyclophosphamide with concurrent versus sequential docetaxel as neoadjuvant treatment in patients with breast cancer
    Vriens, B. E. P. J.
    Aarts, M. J. B.
    de Vries, B.
    van Gastel, S. M.
    Wals, J.
    Smilde, T. J.
    van Warmerdam, L. J. C.
    de Boer, M.
    van Spronsen, D. J.
    Borm, G. F.
    Tjan-Heijnen, V. C. G.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (15) : 3102 - 3110
  • [10] Analysis of the Doxorubicin and Doxorubicinol in the Plasma of Breast Cancer Patients for Monitoring the Toxicity of Doxorubicin
    Harahap, Yahdiana
    Ardiningsih, Puspitasari
    Winarti, Agatha Corintias
    Purwanto, Denni Joko
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2020, 14 : 3469 - 3475
12345